Overview
Pancragen is a synthetic short-chain peptide bioregulator (Khavinson class) developed for research into pancreas-specific cellular signaling. It belongs to a family of short peptides studied for their interactions with regulatory proteins and intracellular pathways relevant to pancreatic tissue.
In research models, Pancragen has been investigated for its effects on transcriptional regulation and intracellular communication in pancreatic-derived cells, with studies exploring its role in cellular renewal, apoptosis pathways, and metabolic enzyme expression. Most published work is in vitro or in animal models; broader physiological claims about blood sugar control or digestive enzyme production in humans remain unestablished and outside the scope of current research.
Mechanism of action
A synthetic short peptide hypothesized to act as a bioregulator by entering pancreatic cells and modulating transcription factors associated with tissue maintenance, based on Khavinson-class research models.
Reported benefits
- ▸Promotes regeneration and repair of pancreatic tissues at the genetic level
- ▸Improves glucose clearance and overall insulin sensitivity
- ▸Regulates insulin and C-peptide levels post-glucose challenge
- ▸Supports both endocrine (hormone) and exocrine (digestive enzyme) functions
- ▸Enhances cell survival by reducing markers of programmed cell death (p53)
- ▸Increases markers of cell renewal such as PCNA and Ki-67
Reported side effects
- ·Injection site redness or discomfort
- ·Mild fatigue
- ·Occasional headache
Often stacked with
LivagenPinealonAlpha-lipoic acidBerberine